Clinical Trial Detail

NCT ID NCT01884285
Title AZD8186 First Time In Patient Ascending Dose Study
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors AstraZeneca
Indications

triple-receptor negative breast cancer

lung non-small cell carcinoma

Advanced Solid Tumor

prostate cancer

Therapies

AZD8186

Abiraterone + AZD8186

AZD8186 + Vistusertib

Age Groups: senior adult

No variant requirements are available.